Skip to main content

Day: July 25, 2025

Traction Uranium Announces LIFE Offering for up to C$833,400

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, July 25, 2025 (GLOBE NEWSWIRE) — Traction Uranium Corp. (CSE: TRAC) (FRA: Z1K) (the “Company” or “Traction”) is pleased to announce that it intends to complete a private placement financing (the “Offering”) of units (each, a “Unit”) at a price of C$0.18 per Unit, with each Unit being comprised of one common share (each, a “Share”) and one Share purchase warrant (“Warrant”). Each Warrant will be entitling the holder to purchase one Share at a price of C$0.24 during the period between the date that is 60 days from Closing (as defined below) and the date that is 24 months from Closing. Closing of the Offering is anticipated to occur on or about August 8, 2025 (“Closing”). The Company notes that it will only complete...

Continue reading

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) — Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) recommended that Regional shareholders vote “FOR”: (1) the approval of the Amended and Restated Agreement and Plan of Merger, dated April 14, 2025 (as amended, the “Merger Agreement”), by and between Regional and SunLink Health Systems, Inc. (the “Merger Proposal”), (2) the approval of the issuance of shares of Regional common stock and Regional Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares (the “Regional Series D preferred...

Continue reading

Grupo Bafar Reports Second quarter 2025 Results

CHIHUAHUA, México, July 25, 2025 (GLOBE NEWSWIRE) — Grupo Bafar, S.A.B. de C.V. (BIVA: BAFARB), a leading and benchmark company in the national food sector, announced its results for the second quarter of 2025, highlighting sustained growth driven by innovation, digitalization, and expansion strategies across all its divisions. Second Quarter 2025 HighlightsNet sales: $7,931 million of pesos, with a growth of 15.5%. Operating income: $1,439 million of pesos, with an operating margin of 18.1%. EBITDA: $1,696 million of pesos, with a registered growth of 13.8%. Net income: $1,580 million of pesos, with a net margin of 19.9%.During the quarter, Grupo Bafar maintained its trajectory of growth and rentability, outperforming again its historic record in quarterly earnings. This performance was a result of a combination of greater...

Continue reading

Kinross announces sale of shares of White Gold

(All dollar amounts are expressed in Canadian dollars, unless otherwise noted.) TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — Kinross Gold Corporation (“Kinross” or the “Company”) (TSX: K, NYSE: KGC) announced today that it has sold an aggregate of 23,681,160 common shares of White Gold Corp. (“White Gold”) representing all of the common shares held by Kinross. The shares represent approximately 12% of the outstanding White Gold common shares. The shares were sold at an average sales price of $0.29 (excluding commission), representing an aggregate sale price of $6,869,905.51. A copy of the early warning report filed by Kinross in connection with the investment will be available on White Gold’s profile on SEDAR+ at www.sedarplus.ca. Alternatively, you may contact Luke Crosby, Senior Vice President, General Counsel and Corporate Secretary...

Continue reading

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended May 31, 2025. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca. “The re-opening of PharmAla’s domestic Canadian distribution has allowed us to execute as much volume in Q2 and Q3 as we did...

Continue reading

Eshallgo Inc. Announced Receipt of Notice from Nasdaq regarding Listing Rule 5550(a)(2).

New York, July 25, 2025 (GLOBE NEWSWIRE) — Shanghai, China July 25, 2025 – Eshallgo, Inc. (NASDAQ:EHGO) (“Eshallgo” or the “Company”) today announced that on July 23, 2025, the Company received a notice from the staff of the Nasdaq Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that for the last 30 consecutive business days, the closing bid price of the Company’s class A ordinary shares was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Nasdaq notification letter has no current effect on the listing or trading of the Company’s class A ordinary shares on Nasdaq.  Pursuant to the Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided with a compliance period of 180 calendar...

Continue reading

ECN Capital Schedules Q2-2025 Conference Call

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — ECN Capital Corp. (TSX: ECN) (“ECN Capital” or “the Company”) announced today that it intends to file its financial statements and management discussion and analysis for the three-month period ended June 30, 2025, after markets close on Thursday, August 7, 2025. The Company will host an analyst briefing to discuss these results commencing at 5:30 PM (ET) on Thursday, August 7, 2025. The call can be accessed as follows:Webcast https://app.webinar.net/pNznM6Eme5L   Toll-free dial in North America  1-888-304-1803International     1-848-488-9277     Presentation slides http://ecncapitalcorp.com/investors/presentations   A telephone replay of the conference call may also be accessed until September 8, 2025, by dialing 1-800-645-7964 and entering the passcode 5036#. About...

Continue reading

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 408. The noncompulsory decision to implement this stock split reflects the Company’s aim to optimize market dynamics, broaden...

Continue reading

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) — Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands, with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today reported its financial results for the fiscal year ended March 31, 2025. Financial Results from Year Ended March 31, 2025 The Company incurred a net loss of approximately $6.8 million during the fiscal year ended March 31, 2025 (“Fiscal 2025”), which includes approximately $0.2 million of net non-cash expenses. This compares to a net loss of approximately $75.4 million during the fiscal year ended March 31, 2024 (“Fiscal 2024”), which included approximately $60.9 million of net non-cash expenses. Net loss decreased by approximately...

Continue reading

VCI Global Launches SecureGPU™ – First Encrypted AI Compute Server for Sovereign and Defense Applications

SecureGPU™ Marks Milestone in Zero-Trust AI Infrastructure; Now Piloting Across Southeast Asia KUALA LUMPUR, Malaysia, July 25, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”), a diversified global holding company with a strategic focus on AI & Robotics, Fintech, Cybersecurity, Capital Market Consultancy, today announced the launch of SecureGPU™, a next-generation encrypted AI compute server developed by its cybersecurity and infrastructure subsidiary, V Gallant Sdn Bhd (“V-Gallant”). SecureGPU™ is the first known server platform integrating GPU compute with real-time PCIe-level encryption, purpose-built for sovereign, defense, and regulated enterprise use. Designed to operate entirely within zero-trust, air-gapped environments, the server enables secure training...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.